



Abbott Laboratories (Pakistan) Limited
 City Office:
 8th Floor Faysal House
 ST-02, Sharah-e-Faisal,
 Karachi-75350
 P.O. Box 7229 Karachi.
 Tel: +92-21-32799018-19

Abbott Laboratories (Pakistan) Limited
 Registered Office:
 Opp. Radio Pakistan Transmission Centre,
 Hyderabad Road, Landhi, Karachi-75120
 P.O. Box 7229 Karachi 74400
 Tel: +92-21-111-Abbott (111-222-688)

April 27, 2026


The General Manager
 Pakistan Stock Exchange Limited
 Stock Exchange Building,
 Stock Exchange Road
 Karachi

Sub: Financial Results for the 1st Quarter ended March 31, 2026

Dear Sir,

We have to inform you that the Board of Directors of our Company in their meeting held on Monday, April 27th, 2026, at 11:00 a.m. virtually at Abbott Laboratories (Pakistan) Limited, considered and approved the financial results of the company as follows:

	<u>Jan-Mar 2026</u>	<u>Jan-Mar 2025</u>
	(Rupees '000)	
SALES-NET		
Local	17,172,927	16,856,488
Export	531,795	489,963
	<u>17,704,722</u>	<u>17,346,451</u>
Cost of Sales	(11,006,914)	(11,504,545)
GROSS PROFIT	<u>6,697,808</u>	<u>5,841,906</u>
Selling and distribution expenses	(2,918,115)	(2,721,303)
Administrative expenses	(380,322)	(303,023)
Other charges	(320,128)	(321,820)
Other income	229,466	260,099
	<u>(3,389,099)</u>	<u>(3,086,047)</u>
	3,308,709	2,755,859
Finance costs	(18,153)	(3,947)
PROFIT BEFORE MINIMUM TAX DIFFERENTIAL, FINAL TAXES AND INCOME TAX	<u>3,290,556</u>	<u>2,751,912</u>
Minimum tax differential	-	(23,624)
Final taxes	-	-
	<u>3,290,556</u>	<u>2,728,288</u>
TAXATION		
- Current	(1,456,902)	(1,207,589)
- Deferred	106,654	78,974
	<u>(1,350,248)</u>	<u>1,128,615</u>
NET PROFIT FOR THE PERIOD	<u>1,940,308</u>	<u>1,599,673</u>
BASIC AND DILUTED EARNINGS PER SHARE (Rs. per share)	<u>19.82</u>	<u>16.34</u>



- 2 -

The Quarterly Report of the Company for the period ended March 31st, 2026 will be transmitted through PUCARS separately, within the specified time.

Yours faithfully,
ABBOTT LABORATORIES (PAKISTAN) LIMITED

SYED ANIS AHMED
CHIEF EXECUTIVE &
MANAGING DIRECTOR

ABBOTT LABORATORIES (PAKISTAN) LIMITED
CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT MARCH 31, 2026

	Note	March 31, 2026 ----- Rupees in '000 ----- (Un-audited)	December 31, 2025 (Audited)
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	6	15,595,021	15,635,851
Intangible assets		778	831
Long-term loans and advances		137,889	141,175
Long-term deposits		32,628	32,628
Long-term prepayments		12,591	12,395
Total Non-current Assets		15,778,907	15,822,880
CURRENT ASSETS			
Stores and spares		664,916	669,690
Stock-in-trade	7	15,141,023	12,447,838
Trade debts		3,011,987	2,820,530
Loans and advances	8	1,340,063	399,086
Trade deposits and short-term prepayments	9	428,023	313,552
Other receivables		1,330,718	1,005,069
Taxation - net		-	-
Cash and bank balances	10	12,473,406	13,337,551
Total Current Assets		34,390,136	30,993,316
TOTAL ASSETS		50,169,043	46,816,196
EQUITY AND LIABILITIES			
SHARE CAPITAL AND RESERVES			
Authorised capital			
200,000,000 ordinary shares of Rs.10 each		2,000,000	2,000,000
Issued, subscribed and paid-up capital	11	979,003	979,003
Reserves			
- Capital		2,195,128	2,073,901
- Revenue		30,512,861	28,572,553
Total Equity		33,686,992	31,625,457
NON-CURRENT LIABILITIES			
Deferred taxation		883,310	989,965
Staff retirement benefits		494,811	494,943
Long-term lease liabilities	12	340,992	329,677
Total Non-current Liabilities		1,719,113	1,814,585
CURRENT LIABILITIES			
Trade and other payables	13	13,793,643	12,198,722
Current maturity of lease liabilities	12	135,548	158,301
Unclaimed dividends		71,073	71,155
Taxation - net		67,231	246,958
Provisions		695,443	701,018
Total Current Liabilities		14,762,938	13,376,154
CONTINGENCIES AND COMMITMENTS	14		
TOTAL EQUITY AND LIABILITIES		50,169,043	46,816,196


The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.



 CHIEF EXECUTIVE



 DIRECTOR




 CHIEF FINANCIAL OFFICER


ABBOTT LABORATORIES (PAKISTAN) LIMITED
CONDENSED INTERIM STATEMENT OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2026
(UN-AUDITED)

	Note	March 31, 2026 ---- Rupees in '000 ----	March 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash generated from operations	17	1,064,956	1,720,598
Income taxes paid		(1,636,630)	(878,681)
Long-term loans and advances - net		3,286	(2,239)
Long-term deposits - net		-	(25,200)
Long-term prepayments - net		(196)	1,627
Net movement in provisions		(5,575)	(12,383)
Net cash (outflow) / inflow from operating activities		(574,159)	803,722
CASH FLOWS FROM INVESTING ACTIVITIES			
Additions to property, plant and equipment		(460,190)	(645,628)
Sale proceeds from disposal of property, plant and equipment		27,539	146,084
Interest income received		188,620	111,921
Net cash outflow from investing activities		(244,031)	(387,623)
CASH FLOWS FROM FINANCING ACTIVITIES			
Finance costs paid		(18,153)	(1,908)
Lease rentals paid		(27,720)	-
Dividends paid		(82)	(2,415)
Net cash outflow from financing activities		(45,955)	(4,323)
NET (DECREASE) / INCREASE IN CASH AND CASH EQUIVALENTS		(864,145)	411,776
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD		13,337,551	6,182,349
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	17.2	12,473,406	6,594,125


The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.



CHIEF EXECUTIVE



DIRECTOR



CHIEF FINANCIAL OFFICER


ABBOTT LABORATORIES (PAKISTAN) LIMITED
CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2026

Share Capital	Reserves				Total	Total Equity
	Capital Reserves		Revenue Reserves			
	Reserve Arising on Merger	Other	General Reserve	Un- appropriated Profit		

----- Rupees in '000 -----

Balance as at January 01, 2025 (Audited)	979,003	46,097	1,704,384	5,338,422	15,656,730	22,745,633	23,724,636
Transactions with owners, recorded directly in equity							
Final dividend for the year ended December 31, 2024 @ Rs. 10.0 per share declared subsequent to the year end	-	-	-	-	(979,003)	(979,003)	(979,003)
Employee benefit cost under IFRS 2- 'Share based payments'	-	-	73,276	-	-	73,276	73,276
Total comprehensive income for the period ended March 31, 2025							
Net profit for the period	-	-	-	-	1,599,673	1,599,673	1,599,673
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	1,599,673	1,599,673	1,599,673
Balance as at March 31, 2025 (Un-audited)	<u>979,003</u>	<u>46,097</u>	<u>1,777,660</u>	<u>5,338,422</u>	<u>16,277,400</u>	<u>23,439,579</u>	<u>24,418,582</u>
Balance as at January 01, 2026 (Audited)	979,003	46,097	2,027,804	5,338,422	23,234,131	30,646,454	31,625,457
Transactions with owners, recorded directly in equity							
Employee benefit cost under IFRS 2- 'Share based payments'	-	-	121,227	-	-	121,227	121,227
Total comprehensive income for the period ended March 31, 2026							
Net profit for the period	-	-	-	-	1,940,308	1,940,308	1,940,308
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	1,940,308	1,940,308	1,940,308
Balance as at March 31, 2026 (Un-audited)	<u>979,003</u>	<u>46,097</u>	<u>2,149,031</u>	<u>5,338,422</u>	<u>25,174,439</u>	<u>32,707,989</u>	<u>33,686,992</u>


The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.



CHIEF EXECUTIVE



DIRECTOR



CHIEF FINANCIAL OFFICER